Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRM1 | P35372 | 1/20 | 0.33 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.33 |
| ▸ | ITGB2 | P05107 | 2/20 | 0.32 |
| ▸ | ICAM1 | P05362 | 2/20 | 0.32 |
| ▸ | ITGAL | P20701 | 2/20 | 0.32 |
| ▸ | ESR1 | P03372 | 1/20 | 0.30 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.30 |
| ▸ | GRM2 | Q14416 | 1/20 | 0.30 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4845206 | 0.88 | GRM2 (0.40) | OPRM1OPRK1ITGB2ICAM1ITGAL | |
| SCHEMBL4843286 | 0.84 | FPR1 (0.35) | OPRM1OPRK1ITGB2ICAM1ITGAL | |
| SCHEMBL4841624 | 0.84 | ITGAL (0.35) | OPRM1OPRK1ITGB2ICAM1ITGAL | |
| SCHEMBL4848701 | 0.82 | REN (0.34) | OPRM1OPRK1ITGB2ICAM1ITGAL | |
| SCHEMBL4845247 | 0.80 | REN (0.34) | ITGB2ICAM1ITGALMCHR1 | |
| SCHEMBL4847245 | 0.80 | ACHE (0.46) | — | |
| SCHEMBL4848901 | 0.80 | MEN1 (0.38) | ITGB2ICAM1ITGAL | |
| SCHEMBL4844697 | 0.80 | PTGER4 (0.40) | — | |
| Dimethylamine SCHEMBL4845222 | 0.79 | ITGAL (0.36) | OPRM1OPRK1ITGB2ICAM1ITGAL | |
| SCHEMBL4841738 | 0.79 | ITGAL (0.35) | OPRM1OPRK1ITGB2ICAM1ITGAL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7342012-B2 | Inhibitors of αLβ2 mediated cell adhesion | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2008-03-11 | — | — | US | disclosed |
| US-20050148602-A1 | Inhibitors of alphaLbeta2 mediated cell adhesion | TANABE SEIYAKU CO., LTD. | 2005-07-07 | — | — | US | disclosed |
| EP-1307455-B1 | INHIBITORS OF ALPHA-L BETA-2 MEDIATED CELL ADHESION | TANABE SEIYAKU CO (JP) | 2005-04-06 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050148602-A1 | Inhibitors of alphaLbeta2 mediated cell adhesion | ITGB2, ITGA2B, ITGB1 | OPRM1 3852/4885OPRK1 3128/4885ITGB2 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.